Gene-based treatment of motor neuron diseases.
Motor neuron diseases (MND), such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), are progressive neurodegenerative diseases that share the common characteristic of upper and/or lower motor neuron degeneration. Therapeutic strategies for MND are designed to confer neuroprotection, using trophic factors, anti-apoptotic proteins, as well as antioxidants and anti-excitotoxicity agents. Although a large number of therapeutic clinical trials have been attempted, none has been shown satisfactory for MND at this time. A variety of strategies have emerged for motor neuron gene transfer. Application of these approaches has yielded therapeutic results in cell culture and animal models, including the SOD1 models of ALS. In this study we describe the gene-based treatment of MND in general, examining the potential viral vector candidates, gene delivery strategies, and main therapeutic approaches currently attempted. Finally, we discuss future directions and potential strategies for more effective motor neuron gene delivery and clinical translation.
Federici
Thais
T
Department of Neuroscience, Cleveland Clinic Foundation, NB2-126A, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.
Boulis
Nicholas M
NM
D000690:Amyotrophic Lateral Sclerosis / Q000628:therapy; D000818:Animals; D017209:Apoptosis / Q000502:physiology; D020868:Gene Silencing; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D016472:Motor Neuron Disease / Q000628:therapy*; D009134:Muscular Atrophy, Spinal / Q000628:therapy